RudaCure (PDG Yongho Kim), une entreprise biotechnologienologique spécialisée dans le développement de médicaments innovants, a annoncé le 3rd that it a été sélectionnée pour le 2025 Agri-Food Venture Development Support Program organized by the Ministère de Agriculture, Food and Rural Affairs, and will commence full-scale development of a vétérinaire gene-based traitement de la douleur.
The 'Agri-Food Venture Development Support Program' is a gouvernement programme de soutien designed to discover and nurture prometteur ventures and startups that will drive high value-added growth in the agri-food industrie. Each year, it selects prometteur projects through rigorous evaluation dans le but de creating future food sources and industrial compétitivité in the agricultural and livestock sectors sur la base de innovant technology.
This project vise à develop a gene therapy that induces analgésique non narcotique effects for application in douleur chronique management of companion animals and high-value animals tels que racehorses. RudaCure a obtenu innovant technology that achieves long-term soulagement de la douleur with a single administration using its proprietary canal ionique-targeted peptide delivered via AAV (Adeno-Associated Virus) vectors.
Selon RudaCure, preliminary test results show that the treatment provides continuous effets analgésiques for more than 3 months with just a single administration. The global vétérinaire traitement de la douleur market is growing rapidly at approximately $2 billion per year, and there is rising demand for innovant treatments that move beyond existing NSAIDs and opioid-based drugs.
le PDG Kim a déclaré : "Being selected for this programme de soutien is recognition of the innovant technology we have accumulated in the vétérinaire gene therapy field. Grâce à cela project, we will accelerate the development of vétérinaire traitement de la douleurs and advance into the marché mondial."
